Given the ability to detect early relapse with high sensitivity, disease monitoring using qRTPCR can be helpful in identifying appropriate candidates for further therapy and allogenic stem cell transplantation (allo‐SCT) before frank hematological relapse, as conventionally CBF‐AML patients in first remission are not considered candidates for allo‐SCT.17 The gene discussed is CEBPZ; the disease is acute myeloid leukemia.